Literature DB >> 26957567

Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria.

Alex van der Steen1, Joost van Rosmalen2, Sonja Kroep1, Frank van Hees1, Ewout W Steyerberg1, Harry J de Koning1, Marjolein van Ballegooijen1, Iris Lansdorp-Vogelaar1.   

Abstract

BACKGROUND: Calibration (estimation of model parameters) compares model outcomes with observed outcomes and explores possible model parameter values to identify the set of values that provides the best fit to the data. The goodness-of-fit (GOF) criterion quantifies the difference between model and observed outcomes. There is no consensus on the most appropriate GOF criterion, because a direct performance comparison of GOF criteria in model calibration is lacking.
METHODS: We systematically compared the performance of commonly used GOF criteria (sum of squared errors [SSE], Pearson chi-square, and a likelihood-based approach [Poisson and/or binomial deviance functions]) in the calibration of selected parameters of the MISCAN-Colon microsimulation model for colorectal cancer. The performance of each GOF criterion was assessed by comparing the 1) root mean squared prediction error (RMSPE) of the selected parameters, 2) computation time of the calibration procedure of various calibration scenarios, and 3) impact on estimated cost-effectiveness ratios.
RESULTS: The likelihood-based deviance resulted in the lowest RMSPE in 4 of 6 calibration scenarios and was close to best in the other 2. The SSE had a 25 times higher RMSPE in a scenario with considerable differences in the values of observed outcomes, whereas the Pearson chi-square had a 60 times higher RMSPE in a scenario with multiple studies measuring the same outcome. In all scenarios, the SSE required the most computation time. The likelihood-based approach estimated the cost-effectiveness ratio most accurately (up to -0.15% relative difference versus 0.44% [SSE] and 13% [Pearson chi-square]).
CONCLUSIONS: The likelihood-based deviance criteria lead to accurate estimation of parameters under various circumstances. These criteria are recommended for calibration in microsimulation disease models in contrast with other commonly used criteria.
© The Author(s) 2016.

Entities:  

Keywords:  cancer screening; goodness-of-fit criterion; microsimulation modeling; model calibration

Mesh:

Year:  2016        PMID: 26957567     DOI: 10.1177/0272989X16636851

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  6 in total

1.  Bayesian Methods for Calibrating Health Policy Models: A Tutorial.

Authors:  Nicolas A Menzies; Djøra I Soeteman; Ankur Pandya; Jane J Kim
Journal:  Pharmacoeconomics       Date:  2017-06       Impact factor: 4.981

2.  Multiobjective Calibration of Disease Simulation Models Using Gaussian Processes.

Authors:  Aditya Sai; Carolina Vivas-Valencia; Thomas F Imperiale; Nan Kong
Journal:  Med Decis Making       Date:  2019-08-02       Impact factor: 2.583

3.  Nonidentifiability in Model Calibration and Implications for Medical Decision Making.

Authors:  Fernando Alarid-Escudero; Richard F MacLehose; Yadira Peralta; Karen M Kuntz; Eva A Enns
Journal:  Med Decis Making       Date:  2018-10       Impact factor: 2.583

4.  Estimating the effects of lockdown timing on COVID-19 cases and deaths in England: A counterfactual modelling study.

Authors:  Kellyn F Arnold; Mark S Gilthorpe; Nisreen A Alwan; Alison J Heppenstall; Georgia D Tomova; Martin McKee; Peter W G Tennant
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.240

5.  How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value.

Authors: 
Journal:  Int J Drug Policy       Date:  2020-04-28

6.  Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis.

Authors:  Christopher J D Wallis; Gerard Morton; Angela Jerath; Raj Satkunasviam; Ewa Szumacher; Sender Herschorn; Ronald T Kodama; Girish S Kulkarni; David Naimark; Robert K Nam
Journal:  MDM Policy Pract       Date:  2017-05-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.